Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-30

Clinical Trial Update: TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update of TALL-104 with Gleevec for chronic myeloid leukemia; the study was terminated and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gleevec (Imatinib)
  • TALL-104

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-06-30